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and also its inhibitory role in lympho-
cyte activation and function (Luger
et al., 1993). Similarly, the reduction
in TRPV6 expression in atopic subjects
might induce a reduction in the intra-
cellular calcium content and conse-
quently in disruption of the epidermal
proliferation/differentiation balance.
In conclusion, although none of
these factors are specific for AD, it is
still the case that together they provide
an aid to understanding the mecha-
nisms of the pathogenesis of AD.
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TO THE EDITOR
This letter is in response to a recent
article (Schmitt et al., 2011) and the
accompanying commentary (Flohr,
2011). The use of the term ‘‘eczema’’
would seem to be a step backward in the
process of ‘‘harmonizing’’ outcome
measures for atopic eczema/atopic
dermatitis (AD). We all recognize that
‘‘eczema’’ is a term used by our pati-
ents and by non-cognoscenti physi-
cians to indicate AD but it is nonspecific
and dermatologists know there are many
types of eczema that clearly are not AD.
In 2004, the World Allergy Organi-
zation (WAO) stated that the term
‘‘eczema’’ would include ‘‘non-atopic
eczema’’ and ‘‘atopic eczema,’’ the latter
being ‘‘eczema in a person of the atopic
constitution’’ (Johansson et al., 2004).
Atopy was defined as specific IgE (sIgE)
reactivity in high responders sensitized
via mucosal surfaces. This definition was
rendered dubious the next year by the
NHANES III study showing sIgE to
common allergens in 54% of the United
States population (Arbes et al., 2005) and
by numerous reports since 2006 indica-
ting that the transcutaneous route
may be a major pathway for IgE sensi-
tization (Weidinger et al., 2006; van den
Oord and Sheikh, 2009; Brown et al.,
2011). Infants often have typical disease
well before relevant sIgE levels. They do
not need testing to be properly diagnosed
as AD, which might well predispose to
atopy; routine sIgE tests are not usually
indicated (Boyce et al., 2010).Abbreviations: AD, atopic dermatitis; sIgE, specific IgE; WAO, World Allergy Organization
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The terminology imposed by the
WAO reflects allergists’ poor understand-
ing of the extensive eczema/dermatitis
spectrum. The requirement for IgE testing
in their diagnostic scheme goes beyond
good clinical and scientific standards and
adds unnecessarily to health care costs.
That they were able to get a few
dermatologists to sign on is unfortunate,
especially now that the terminology has
crept into a scientific journal such as the
Journal of Investigative Dermatology. The
preceding comments are not meant to
detract from the efforts made by Schmitt,
Williams, and others to seek harmoniza-
tion of outcome measures for AD. It does
seem clear that we should, simulta-
neously, seek international agreement
on the terminology and definition of
AD. It is time to face these diversions
and seek global agreement on what is
best for our patients. Science cannot
proceed without internationally accepta-
ble definitions and logical terminology.
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TO THE EDITOR
In his comment on our paper recently
published in the Journal of Investiga-
tive Dermatology (Schmitt et al., 2011),
Dr Hanifin (2011) expresses concerns
that variants in the nomenclature may
impede the efforts of the international
community to harmonize outcome
measures for studies on atopic ecze-
ma/atopic dermatitis (Schmitt and
Williams, 2010).
Our call for a standardization of
outcome measures for atopic eczema
trials and for record keeping in clini-
cal practice resulted in considerable
interest and support from the interna-
tional research community and patient
groups throughout the world (Schmitt
et al., 2011). To harness such interest,
the Harmonising Outcome Measures for
Eczema (HOME) initiative (http://www.
homeforeczema.org) was founded in
July 2010 at the International Sympo-
sium on Atopic Dermatitis/New Trends
in Allergy meeting in Munich, Germany,
consisting of about 40 clinical researchers
and outcomes research methodologists
(Schmitt and Williams, 2010). At this
meeting, the majority of participants,
including Hanifin, expressed a clear
interest in proceeding further into
working on identifying core outcomes
for eczema research. A further HOME
meeting was held in Amsterdam in
June 2011, which also included indus-
try scientists and methodologists who
endorsed the core outcome domains
(i.e., the aspects of atopic eczema that
should be regularly measured in future
clinical trials) identified in the initial
international Delphi exercise (Schmitt
et al., 2011). This has led to a series
of projects to identify which mea-
sures are best suited for such domains.
The HOME initiative is also linked with
other international outcome measures
initiatives beyond the field of derma-
tology, such as COMET (Sinha et al.,
2008, 2009) and OMERACT (Tugwell
and Boers, 1993).
There are two main reasons why
we decided to call our initiative the
Harmonizing Outcomes Measures on
Eczema (HOME)-initiative. First, as
Hanifin correctly emphasizes, ‘‘eczema’’
is a term commonly used by patients
and by many physicians around the
world. As our initiative has a strong
focus on patients’ perspectives, it is a
necessary prerequisite for its success toAbbreviations: HOME, Harmonising Outcome Measures for Eczema; WAO, World Allergy Organization
www.jidonline.org 473
J Schmitt et al.
Atopic Eczema: A Call for Harmonization
